Abstracts tagged "Epidemiology"

Abstract Number: 1891 • ACR Convergence 2024
Association of Physical Activity Levels on Chronic Opioid Use in Radiographic Axial Spondylitis Patients
Rutvin Kyada¹, Jean Liew², Maureen Dubreuil³, Matthew Brown⁴, Mariko Ishimori⁵, John Reveille⁶, Michael Ward⁷, Michael Weisman⁸ and Lianne S Gensler⁹, ¹Boston University, Boston, MA, ²Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ³Section of Rheumatology, Boston University School of Medicine, Boston, MA, ⁴King's College London, London, United Kingdom, ⁵Cedars-Sinai Health System, Los Angeles, CA, ⁶UTHealth Houston Division of Rheumatology, Houston, ⁷NIH, Bethesda, MD, ⁸Stanford University, Los Angeles, CA, ⁹Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Pain remains a common symptom of axial spondyloarthritis (axSpA) despite availability of effective therapies. Physical activity may benefit pain and is guideline recommended but…
Abstract Number: 2031 • ACR Convergence 2024
A Contemporary Assessment of the Burden of Malignancy in IgG4-Related Disease
Grace McMahon¹, Isha Jha¹, Guy Katz¹, Cory Perugino¹, Ana Fernandes¹, John Stone² and Zachary Wallace³, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital , Harvard Medical School, Concord, MA, ³Massachusetts General Hospital, Newton, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a fibro-inflammatory disorder that can affect nearly any organ. Because of the often tumefactive nature of IgG4-RD and its typical…
Abstract Number: 2421 • ACR Convergence 2024
Trends in Glucocorticoid Use in Systemic Lupus Erythematosus in a Population-Based Inception Cohort from 1976 to 2018: The Lupus Midwest Network
Mariana Gonzalez-Trevino¹, Jaime Flores Gouyonnet¹, Qiping Xu², Cassondra Hulshizer³, Jose Meade-Aguilar⁴, Erika Navarro-Mendoza¹, Mario Bautista-Vargas⁵, Gabriel Figueroa-Parra⁶, Alain Sanchez-Rodriguez⁷, Maria Cuellar-Gutierrez¹, Andrew C. Hanson⁸, Cynthia Crowson¹ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic Health System - Mankato, Mankato, MN, ³Mayo Clinic, Utica, MN, ⁴Boston University/Boston Medical Center, Boston, MA, ⁵Mayo Clinic, Rochester, Minnesota, USA., Rochester, MN, ⁶Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁷Mayo Clinic College of Medicine and Science, Rochester, MN, ⁸Mayo Clinic, Rochester
Background/Purpose: We examined the patterns of glucocorticoid (GC) use and the temporal trends of GC initiation, discontinuation, and reduction over four decades in a population-based…
Abstract Number: 2666 • ACR Convergence 2024
The Risk for Development of Myositis Is Not Increased After COVID-19 Vaccination Among U.S. Veterans
Caleb Hernandez¹, Naomi Schlesinger², Jorge Rojas³, Jessica A Walsh⁴, Tawnie Braaten², Gary Kunkel⁵, Makoto Jones², Sauer brian⁶, Julio Facelli¹, grant Cannon⁷ and Dorota Lebiedz-Odrobina⁸, ¹University of Utah, Salt Lake City, ²University of Utah, Salt Lake City, UT, ³Seattle VA, Mexico, Mexico, ⁴Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ⁵University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁶Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁷University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁸University of Utah, Cottonwood Heights, UT
Background/Purpose: Several case reports and case series of idiopathic inflammatory myositis (IIM) following COVID-19 vaccination have been reported. This study evaluated the association of prior…
Abstract Number: 0160 • ACR Convergence 2024
Supplement Use in a Diverse Cohort of Individuals with SLE
Russell Ellyson¹, Jinoos Yazdany², S. Sam Lim³, Brad Pearce³ and Laura Plantinga⁴, ¹Alameda Health System, Highland Hospital, Oakland, CA, ²UCSF, San Francisco, CA, ³Emory University, Atlanta, GA, ⁴University of California, San Francisco, San Francisco, CA
Background/Purpose: Supplement use among individuals with SLE is not well-characterized, despite potential effects of some supplements on SLE activity or on treatments for SLE or…
Abstract Number: 0412 • ACR Convergence 2024
Impact of Approval of Biologic DMARDs on JIA Outcomes in a Single Center
Anna Sutton¹, Erin Balay-Dustrude¹, Beth A Mueller¹ and Susan Shenoi², ¹University of Washington, Seattle, WA, ²Seattle Children's Hospital and Research Center, Mercer Island, WA, WA
Background/Purpose: In clinical trials, biologic disease-modifying antirheumatic drugs (bDMARDs) for juvenile idiopathic arthritis (JIA) have demonstrated good efficacy. However, less is known about the impact…
Abstract Number: 0687 • ACR Convergence 2024
Patterns of Disease Progression in Early Systemic Sclerosis Patients with Interstitial Lung Disease
Lorenzo Beretta¹, Alessandro Santaniello², Silvia Bosello³, Enrico De Lorenzis⁴, Gerlando Natalello⁵, Nicoletta Del Papa⁶, Silvia Cavalli⁷, Devis Benfaremo⁸, Giacomo De Luca⁹, Corrado Campochiaro¹⁰, Lorenzo Cavagna¹¹, Veronica Codullo¹², Francesco Bonomi¹³, gaia Montanelli¹⁴, Adriana Severino¹⁵, Monica Caronni², Barbara Vigone², Silvia Bellando-Randone¹⁶, Carlomaurizio Montecucco¹⁷, Marco Matucci-Cerinic¹⁸, Lorenzo Dagna¹⁹, Gianluca Moroncini⁸, Roberto Caporali²⁰ and Chiara Bellocchi²¹, ¹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Milan, Italy, ²Fondazione IRCCS Ca' Granda Ospedale Policlinico di Milano, MILANO, Italy, ³FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI- IRCCS, Rome, Rome, Italy, ⁴Catholic University of the Sacred Heart, Roma, Rome, Italy, ⁵Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Rome, Italy, ⁶ASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini-CTO, Milano, Milan, Italy, ⁷University of Milan, Milan, Milan, Italy, ⁸Marche Polytechnic University, Ancona, Italy, ⁹Vita-Salute San Raffaele University & IRCCS San Raffaele Hospital, Milan, Milan, Italy, ¹⁰IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ¹¹University of Pavia and Fondazione IRCCS Policlinico San Matteo Hospital of Pavia, Pavia, Pavia, Italy, ¹²Division of Rheumatology - Policlinico San Matteo, Pavia, Italy, Pavia, Lombardia, Italy, ¹³Azienda Ospedaliera Universitaria Careggi, Florence, Florence, Italy, ¹⁴Fondazione IRCCS Ca' Granda Ospedale Policlinico di Milano, Milan, Italy, ¹⁵Fondazione IRCCS Ca' Granda Ospedale Policlinico di Milano, Milan, Milan, Italy, ¹⁶University of Florence, Florence, Florence, Italy, ¹⁷IRCCS policlinico S. Matteo foundation, University of Pavia, Pavia, Italy, ¹⁸University San Raffaele Milano, Milano, Milan, Italy, ¹⁹Ospedale San Raffaele, Milano, Italy, ²⁰Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, ²¹Università degli Studi di Milano, IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy
Background/Purpose: Understanding the trajectory of disease progression in SSc-ILD is crucial for effective patient management and prognostication. Trajectory modeling offers a novel approach to deciphering…
Abstract Number: 0990 • ACR Convergence 2024
Predictors of Adverse Events and Complications in Cirrhotic Patients with Rheumatoid Arthritis: A Nationwide Analysis
Nidaa Rasheed¹, Humzah Iqbal² and Candice Reyes³, ¹UCSF Fresno, Fresno, CA, ²UCSF FRESNO, FRESNO, ³VACCHCS, Fresno, CA
Background/Purpose: Cirrhosis is associated with a host of complications such as coagulopathy, renal impairment, esophageal varices, peritonitis, and increased mortality. Rheumatoid arthritis (RA) is a…
Abstract Number: 1093 • ACR Convergence 2024
Risk of Dementia in Patients with Gout: Potential Impact of Survival Bias
Joshua Baker¹, Lindsay Helget², chung-Chou Chang³, Bryant England², Brian Coburn¹, Harlan Sayles², Punyasha Roul⁴ and Ted Mikuls², ¹University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³University of Pittsburgh, Pittsburgh, PA, ⁴UNMC, Omaha, NE
Background/Purpose: Prior studies reported a lower risk of dementia among patients with gout suggesting that hyperuricemia might play a neuroprotective role. However, risk estimates for…
Abstract Number: 1343 • ACR Convergence 2024
Heightened Gout Risk in Patients with Rheumatoid Arthritis: A National Cohort Study
Seonyoung Kang¹, Yeonghee Eun², Kyungdo Han³, Jinhyung Jung⁴, Seulkee Lee⁵, Hoon-Suk Cha⁶, Hyungjin Kim⁷, Jaejoon Lee⁵ and Dong Wook Shin⁸, ¹Samsung Medical Center, Gangnam-gu, Seoul, South Korea, ²Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Jongno-gu, Seoul, Republic of Korea, ³Department of Statistics and Actuarial Science, Soongsil University, Seoul, Republic of Korea, ⁴Department of Medical Statistics, College of Medicine, Catholic University of Korea, Seoul, Republic of Korea, ⁵Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ⁶Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ⁷Department of Medical Humanities, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ⁸Department of Family Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul
Background/Purpose: Although gout is a prevalent disease, the coexistence of rheumatoid arthritis (RA) and gout has been considered unusual. Only several case reports describing the…
Abstract Number: 1748 • ACR Convergence 2024
Fracture Incidence Rates in Persons with Rheumatoid Arthritis by Disease Activity Level
Rachel Elam¹, Emma Kersey², Jing Li³, Gabriela Schmajuk⁴ and Laura Carbone⁵, ¹Augusta University, Evans, GA, ²University of California San Francisco, San Francisco, CA, ³University of California, San Francisco, San Francisco, CA, ⁴UCSF / SFVA, San Francisco, CA, ⁵Augusta University, Augusta, GA
Background/Purpose: Fracture incidence rates (IRs) are higher in men and women with rheumatoid arthritis (RA) than those without RA, especially for those with higher RA…
Abstract Number: 1892 • ACR Convergence 2024
Early Tumor Necrosis Factor Inhibitor Initiation and Chronic Opioid Use in Individuals with Axial Spondyloarthritis
Eva Petrow¹, Jose Meade Aguilar², Christine Peloquin³, S. Reza Jafarzadeh³, Tuhina Neogi³, Maureen Dubreuil⁴ and Jean Liew³, ¹Boston University/Boston Medical Center, Boston, MA, ²Boston Medical Center, Boston, MA, ³Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁴Section of Rheumatology, Boston University School of Medicine, Boston, MA
Background/Purpose: Patients with axial spondyloarthritis (axSpA) bear a substantial burden of chronic opioid use despite the availability of effective treatments like tumor necrosis factor inhibitors…
Abstract Number: 2050 • ACR Convergence 2024
Clinical Enthesitis Concerns Half the Patients with Psoriatic Arthritis, Is More Frequent in Trials Than in Observational Studies and Is Assessed Heterogeneously: A Systematic Review with Meta-analysis of 84,262 Patients from 212 Studies
caroline pignon¹, Laure Gossec², Bruno Fautrel³, Clementina López Medina⁴ and Noemie bibas⁵, ¹Faculté de médecine Créteil, PARIS, France, ²Sorbonne Université, Paris, France, ³INSERM, UMRS 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Sorbonne University – Assistance Publique-Hôpitaux de Paris, Département de Rhumatologie, Hôpital Pitié-Salpêtrière, Paris, Ile-de-France, France, ⁴Reina Sofia University Hospital, Cordoba, Spain, ⁵Sorbonne Université, paris
Background/Purpose: Enthesitis is considered a hallmark of psoriatic arthritis (PsA), however data on the frequency and consequences of enthesitis are conflicting. To analyze clinical enthesitis in…
Abstract Number: 2469 • ACR Convergence 2024
Machine Learning Identifies Oesophageal Symptoms as a New Red Flag for for Very Early Diagnosis of Systemic Sclerosis (VEDOSS): A EUSTAR Analysis
Stefano Di Donato¹, Vishal Kakkar², Silvia Bellando-Randone³, Marco Matucci-Cerinic⁴ and Francesco Del Galdo², and EUSTAR collaborators, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, ²University of Leeds, Leeds, United Kingdom, ³University of Florence, Florence, Florence, Italy, ⁴University San Raffaele Milano, Milano, Milan, Italy
Background/Purpose: The analysis of the EUSTAR Very Early Diagnosis of Systemic Sclerosis (VEDOSS) study has identified the risk of progression to fulfil 2013 ACR/EULAR classification…
Abstract Number: 2679 • ACR Convergence 2024
Predictors of Fracture in SLE: A Longitudinal Cohort Study
Kristen Chao¹, Andrea Fava², Daniel Goldman³, Laurence Magder⁴ and Michelle Petri³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: Fractures are one of the most common damage items in the SLICC/ACR Damage Index. Although commonly attributed to corticosteroid use, the complexity of ways…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.